Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.19) earnings per share for the quarter, Zacks reports.
Mymd Pharmaceuticals Stock Down 15.6%
QCLS opened at $4.33 on Friday. The company has a market cap of $18.06 million, a P/E ratio of -0.04 and a beta of 2.11. Mymd Pharmaceuticals has a fifty-two week low of $2.50 and a fifty-two week high of $33.56.
Analyst Ratings Changes
Separately, Weiss Ratings began coverage on shares of Mymd Pharmaceuticals in a research note on Wednesday. They set a “sell (e+)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Mymd Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.
The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.
Read More
- Five stocks we like better than Mymd Pharmaceuticals
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
